"paper"

Our paper of the month highlights the findings of the stage 2 interim analysis from the first cycle of MND SMART, a phase 3, multi-arm, randomised, adaptive platform trial conducted across 20 centres in the UK.

Our paper of the month for November presents the findings from two large trials comparing the safety and efficacy of evobrutinib with teriflunomide in adults with a diagnosis of relapsing MS.

Our Paper of the Month for October is a phase 2, double-blind, randomised, placebo-controlled trial investigating the efficacy of a monoclonal antibody (Lu AG09222) that inhibits PACAP signalling.

The EAN strongly endorses the newly published EBC perspective paper on Rethinking Alzheimer's Disease given that Alzheimer's disease is a devastating neurological disease affecting more and more people in Europe and across the world due to ageing societies.

Our paper of the month for September updates the 2020 Lancet Commission report on the identification of risk factors for dementia, adding two more risk factors to the list.

Our paper of the month for August is a randomised controlled trial evaluating tenecteplase administered 4.5 to 24 hours after stroke onset in 516 Chinese patients.

Our paper of the month is an observational cohort study exploring the link between sleep measures and AD pathology in 319 participants (mean ± SD age: 61.5 ± 5.4 years; 47% female) from the Rotterdam Study, a prospective population-based study conducted in the Netherlands.

Our paper of the month reports the result of a trial investigating the safety and the potential efficacy of intravenous treatment with acyl-ghrelin in improving neurological outcome in patients in a coma after cardiac arrest.

In our Paper of the Month for May, researchers traced the trajectory of Alzheimers biomarkers, for the first time employing a longitudinal design, with impressive, groundbreaking results.

Our paper of the month for April is the latest work by the Global Burden of Diseases Collaborator Network, which has found that neurological conditions are the leading cause of ill health and disability worldwide, with over 3.4 billion people worldwide are affected.

Our Paper of the month for March is a retrospective longitudinal study emphasizing the important role of cortical myelin dynamics in determining neurodegeneration and clinical progression in MS.

Our paper of the month for February is an open-label extension study to assess the long-term efficacy and safety of cerliponase in padiatric patients with CLN2 disease.

A retrospective, multicentre, cross-sectional study aiming to evaluate the performance of cortical lesions and the central vein sign in differentiating multiple sclerosis from other conditions with brain white matter lesions.

This study presents the results of a clinical trial investigating whether apixaban, compared to aspirin, would be associated with reduced risk of stroke or systemic embolism, with a tolerably low risk of major bleeding.

Our Paper of the Month for November is a meta-analysis investigating the safety and efficacy of oral anticoagulation for prevention of major cardiovascular events in patients with atrial fibrillation and previous spontaneous intracranial haemorrhage.